$AVR
Anteris’ DurAVR THV Demonstrates 1% Heart Failure Hospitalization, Single-Digit Gradients and No Valve-Related Deaths at 1 Year in Patients with Small Aortic Annuli
- Anteris Technologies reported one-year DurAVR heart valve results in patients with severe aortic valve narrowing and small valve openings.
- Among 100 patients pooled from EMBARK and early feasibility studies, 1% were hospitalized for heart failure and no valve-related deaths were reported through one year.
- Mean pressure across the valve fell from 48.1 to 8.9 mmHg, with no moderate or severe leakage around the valve.
- The share of patients with no or mild symptoms rose from 39% to 96%.
- At one year, all-cause mortality was 6%, stroke occurred in 3% and 9% received a new permanent pacemaker.
- At 30 days, 97% were free from moderate or severe mismatch between the valve opening and body size.
- The pivotal PARADIGM trial is enrolling in the United States and Europe to compare DurAVR with commercially available transcatheter valves.
https://t.co/7cI7T5smeY
$MSGR
-JPMorgan initiates MSG Rangers coverage at Overweight
-The firm said MSG Rangers offers pure-play ownership in the New York Rangers following a spinout from MSG Sports
-Sets $310 target
https://t.co/Z9CUDEbzFQ
$MRVL
-Stifel cuts Marvell target $280 from $370
-Stifel expects Marvell’s October quarter revenue to come in at $3.15 billion, up 15.0% sequentially, consistent with preliminary results announced by the company
-Maintains Buy rating
https://t.co/OzadFlmT6H
$LSPD
-Truist lowers Lightspeed Commerce target to $10 from $11
Hold
-
$MAR
-Morgan Stanley raises Marriot International target to $431 from $403
Overweight
-
$MH
-JPMorgan raises McGraw Hill target to $19 from $18
Overweight
-
$MNR
-Johnson ie downgrades Mach Natural Resources to Accumulate from Buy
$13 target
$LEU
-Guggenheim raises Centrus Energy target to $172 from $167
Buy
-
$LFTO
-Tigress Financial raises Liftoff Mobile target to $42 from $41
Buy
-
$LOW
-KGI downgrades Lowe's to Neutral from Outpperfrm
$231 target
-
$LPLA
Keefe Bruyette lower LPL Financial target to $350 from $395
Outperform
$KVYO
-Cowen raises Klaviyo target ro $30 from $26 on AI growth potential
-Cowen sees 20%-plus growth durability with a rising AI tailwind for the company.
-Reiterates Buy rating
https://t.co/rQltTWQhfn
$KLIC
-Needham lowers Kulicke and Soffa target to $80 from $115
Buy
-B. Riley raises target to $71 from 470
Neutral
-
$KOF
-Barclays raises Coca-Cola FEMSA target to $128 from $125
= Weight
$JNJ
-JPMorgan raises Johnson & Johnson target to $300 from $285
Neutral
-
$KEYS
-Barclays raises Keysight target to $439 from $429
Overweight
-UBS lowers target to $380 from $440
Buy
-Baird lowers target to $375 from $430
Outperform
-Bank of America lowers target to $375 from $405
Buy
-Wells Fargo lowers target to $350 from $405
Overweight
-Citi lowers target to $345 from $400
Buy
$INTU
-Jefferies lowers Intuit target to $445 from $500
Buy
-Barclays lowers target to $445 from $500
Buy
-BMO lowers target to $375 from $412
Outperform
-Cowen maintains $350 target
Hold
-Evercore lowers target to $335 from $400
Buy
-RBC lowers target to $330 from $385
Outperform
-JPMorgan lowers target to $321 from $331
Neutral
-Wells Fargo lowers target to $320 from $330
= Weight
-UBS lowers target to $315 from $360
Neutral
-Bank of America lowers target to $310 from $350
Neutral
-Morgan Stanley lowers target to $310 from $315
= Weight
-Piper Sandler lowers target to $270 from 290
Underweight
$INCY
-Mizuho raises Incyte target to $148 from $137
-Mizuho said upcoming catalysts, along with the potential approval and launch of povo in hidradenitis suppurativa, could move the stock
-Reiterates Outperform rating
https://t.co/A92BiB8GyI
$HUM
-Cowen upgrades Humana to Buy from Hold
Raises target to $485 from $430
-
$IDYA
-JPMorgan lowers IDEAYA Biosciences target to $55 from $62
Overweight
-
$IMDX
-Lake Street lowers Insight Molecular Diagnostics target to $9 from $12
Buy
$HGV
-Morgan Stanley lowers Hilton Grand Vacations target to $52 from $54
= Weight
-
$HIMS
-Bank of America lowers Hims & Hers Health target to $21 from $26
Neutral
-
$HPE
-UBS lowers Hewlett Packard Enterprise target to $52 from $66
Neutral
-
$HST
-Morgan Stan;ey raises Host Hotels target to $25 from $24
= Weight
$GLOB
-Susquehanna lowers Globant target to $66 from $270
Positive
-Needham raises target to $50 from $45
Buy
-Cowen raises target to $46 from $45
Buy
-Truist raises target to $44 from $38
Hold
-Wells Fargo lowers target to $44 from $48
= Weight
-Jefferies raises target to $40 from $35
Hold
-William Blair maintains Market Perform rating
$FWRD
=Susquehanna raises Forward Air target to $29 from $25
Positive
-
$GAP
-UBS lowers Gap target to $36 from $42
Buy
-Telsey lowers target to $26 from $34
Outperform
-Baird lowers target to $26 from $29
Outperform
-BTIG lowers target to $26 from $27
Buy
-Bank of America lowers target to $23 from $27
Neutral
-BMO lowers target to $21 from $24
Market Perform
-Barclays lowers target to $20 from $23
= Weight
$FTS
-Jefferies downgrades Fortis stock to Underperform from Hold on Arizona regulatory risk
-Both new Democratic Arizona Corporation Commissioners for 2027 have pledged to oppose formula rates, creating future uncertainty
-Raises target to C$72 from C$70
https://t.co/e5vE0SMEjt
$FANG
-Wells Fargo raises target to $250 from 244
Overweight
-Raymond James lowers target to $246 from $256
Strong Buy
-
$FLY
-JPMorgan lowers Firefly Aerospace target to $32 from $40
Overweight
-
$FPS
-Morgan Stanley lowers Forgent Power target to $40 from $45
= Weight
$EWTX
-JPMorgan raises Edgewise Therapeutics target to $69 from $60
Overweight
$EXPD
-Susquehanna raises Expeditors target to $210 from $190
Neutral
-Cowen raises target to $196 from $189
Upgrades to Hold from Sell
-
$EXPE
-Bernstein lowers Expedia target to $261 from $310
Market Perform